Circulating miR-499a-5p Is a Potential Biomarker of MYH7—Associated Hypertrophic Cardiomyopathy

Figures

• 

  Figure 1. The comparison of the profiles of circulating miRNAs in patients with HCM (n = 9) and controls (n = 6). On the graph, the X-axis represents the values of the fold change (FC) in miRNA levels, the Y-axis represents the p values, all in a logarithmic scale. The dotted line indicates threshold for statistical significance p = 0.05; solid line—threshold for statistical significance adjusted p-value (p.adj) = 0.05; dots—miRNAs.

• 

  Figure 2. Plasma levels of miR-208b and miR-499a-5p in 29 HCM patients and 32 healthy controls as determined by RT-qPCR. Here and below, miRNA levels were calculated relative to cel-miR-39-5p using the delta-delta Ct method. Data is presented using a scatter plot (mean with SD). Differences in miRNA levels between HCM patients and healthy controls were insignificant (p > 0.05) according to a Mann-Whitney U test. The green dots define levels of miR-208b and miR-499a-5p in controls, blue dots and red dots—levels of miR-208b and miR-499a-5p, respectively, in patients with HCM. HCM—hypertrophic cardiomyopathy.

• 

  Figure 3. Level of circulating miR-499a-5p in each HCM patient depending on sequencing data of HCM-associated genes. ND—patients in whom mutations in sequenced genes were not determined.

• 

  Figure 4. Levels of miR-499a-5p in carriers of mutations in MYH7 gene (n = 7), in carriers of mutations in MYBPC3 gene (n = 8), in mixed group of non-MYH7 and non-MYBPC3 mutations carriers and of genotype-negative patients (n = 14); and controls (n = 32) as determined by RT-qPCR. Significant differences were determined by using a Mann-Whitney U test.

• 

  Figure 5. The ROC curve analysis of circulating miR-499a-5p for detecting MYH7-positive HCM patients. ROC—receiver operating characteristic; AUC—area under the curve.